SARC 044 Open for Enrollment

SARC’s newest clinical trial, SARC044, is now open for enrollment! This trial, led by Study PI, Dr. Candace Haddox of Dana Farber Cancer Institute, in collaboration with Cogent Biosciences, DFCI, and The Life Raft Group, aims to enroll patients with GIST who have previously progressed on sunitinib. The trial will involve treating patients with bezuclastinib in combination with sunitinib. Enrollment is currently open at Dana Farber Cancer Institute, Oregon Health & Science University, and Fox Chase Cancer Center, with a fourth site set to open in Florida this fall. For more information, please click here.